Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Founder operating in the Pharmaceutical space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Michael Anstey
Co-Founder and Chief Operating Officer of Proteorex Therapeutics Inc.
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
Follow Michael Anstey:
About Cambridge Innovation Capital, Proteorex Therapeutics Inc.: Expanding horizons to find cures
Stephen Smith
Co-Founder of Pear Therapeutics
Stephen Smith received his B.A from Harvard University, J.D. from Columbia University, and M.Ed from Harvard University School of Education. After law school, Stephen served as an assistant district attorney in New York. He later joined the staff of the Senate Judiciary and Foreign Relations Committees. After leaving the Senate, Stephen worked at Conflict Management Group; a nonprofit associated with Harvard Law School, and taught in the advanced program on negotiation at Harvard University Law School. As part of his work at Conflict Management, Stephen consulted with global clients including the Organization of African Unity, the World Bank, the Inter-American Development Bank and the parties in the Irish Peace process. Stephen is a three-time recipient of the Danforth Award for excellence in teaching at Harvard University and is also the winner of the Lyndehurst Foundation Prize for social and artistic achievement. For the past twenty years, Stephen has been on the Kennedy board of Joseph P. Kennedy Enterprises, the Kennedy family investment office. He has delivered keynote presentations at the annual conferences of the Family Firm Institute and the Family Office Exchange– the two major family business organizations. Stephen has also served on the board of the John F. Kennedy Library, the Robert F. Kennedy Memorial, Citizens Energy, the Northeastern University School of Public Policy, and INCAE Business School and the advisory board of the Joslin Diabetes Center at Harvard Medical School. Stephen is a Fellow at the International Economic Alliance, an organization dedicated to promoting innovative international trade. As a partner and board member, Stephen is actively involved in a number of medical and green technology businesses, including Emlink, which develops, designs and manages sustainable technology; The Marwood Group, a healthcare-focused strategic advisory and financial services firm; and Pear Therapeutics, a medical software company. Stephen was Deputy Campaign Manager for Senator Edward Kennedy during his Presidential and Senatorial campaigns, Youth Coordinator for the campaign of Mario Cuomo, served on the New England Steering Committee for the Obama presidential campaign, and continues to be active in Democratic politics.
Follow Stephen Smith:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Philippe Leboulch
Founder & Co-Chair of Scientific Advisory Board of Bluebird Bio
Head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; Professor of Medicine, University of Paris; and Visiting Professor, Harvard Philippe Leboulch is a scientific founder of bluebird bio. He serves as the co-chairman of its Scientific Advisory Board and leader of the LentiGlobin® project. He is a professor of medicine and cell biology at the University of Paris and visiting professor at Harvard Medical School. Philippe is also the director of the Institute of Emerging Diseases and Innovative Therapies of the CEA near Paris and director of an INSERM research unit. He maintains a research laboratory in the genetics division of the Brigham & Women’s Hospital at Harvard Medical School, where he previously served as a full-time faculty member for 15 years after a postdoctoral fellowship at MIT. Philippe is an expert in vectorology and hematopoietic gene therapy, with special emphasis on the beta-hemoglobinopathies. He has been published extensively in high-impact journals and is a regularly invited speaker at major international conferences. Philippe was a member of the Editorial Board of Blood, the Journal of the American Society of Hematology. He has served on major committees of the National Institutes of Health and the American Society of Gene Therapy. Philippe has received numerous NIH grant awards and prizes that include the Grand Prize Etancelin of the French National Academy of Sciences.
Follow Philippe Leboulch:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Amy Schulman
Executive Chairman & Co-Founder of Lyndra Therapeutics
Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris Partner’s Boston office as a Healthcare Venture Partner in 2014, simultaneously assuming the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. In July 2015 Amy co-founded Lyndra where she is Chief Executive Officer and President. Amy is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Amy joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. Prior to that, Amy led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum and Chapstick. Amy also served as Executive Vice President and General Counsel of Pfizer Inc. Key accomplishments include: revitalization of the ChapStick brand; regulatory filing for Lipitor OTC; rapid growth of Emergen-C and increased Europe profitability. Amy originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, Amy spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a Member of the Board and Executive Policy Committees and built and led the international law firm’s mass tort and class-action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare and Pfizer. Amy began her career in litigation with Cleary Gottlieb Steen & Hamilton. Amy’s accomplishments have earned her accolades from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” Amy also has been recognized by The American Bar Association, which honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2009 Forbes magazine included her on its inaugural list of “The World’s Most Powerful Women.” Amy serves on the Boards of Directors of Alnylam Pharmaceuticals, Arsanis, Biosciences, Arsia Therapeutics, BIND Therapeutics, Blue Buffalo, Lyndra, and SQZ Biotech. A Phi Beta Kappa Graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Follow Amy Schulman:
About Arsia Therapeutics, Harvard Business School, Lyndra Therapeutics, Polaris Partners, Suono Bio: Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Richard Friesner
Co-Founder of Schrödinger
Richard A. Friesner is Professor of Chemistry at Columbia University and Director of the Columbia Center for Biomolecular Simulation. He is a member of the National Academy of Sciences and American Academy of Arts of Sciences, and has been awarded a Sloan Foundation Fellowship, Camille and Henry Dreyfus Teacher-Scholar Award, and an NIH Research Career Development Award. Current interests include quantum chemistry, development of potential functions for molecular simulation, continuum electrostatic models, and protein folding. Dr. Friesner is a co-founder of Schrödinger, and a member of Schrödinger’s Board of Directors.
Follow Richard Friesner:
About Columbia University, Schrödinger: Schrödinger develops a chemical simulation software for use in pharmaceutical and biotechnology research.
Venky Soundararajan
Co-Founder & Chief Scientific Officer of nference
Follow Venky Soundararajan:
About nference: nference.inc, provides an AI based software platform that synthesizes siloed biomedical knowledge for insights and makes it computable.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
David Sabatini
Founder of KSQ Therapeutics
David Sabatini is a Member of the Whitehead Institute for Biomedical Research, and he is Senior Associate Member at the Broad Institute, Member of the Koch Institute for Integrative Cancer Research, and a Professor of Biology, all with the Massachusetts Institute of Technology (MIT). He is also a Howard Hughes Medical Institute Investigator. David and his lab at the Whitehead Institute study the basic mechanisms that regulate growth, the processes whereby cells and organisms accumulate mass and increase in size, as well as the role of metabolism in cancer and in the mechanisms that control the effects of dietary restriction on tumorigenesis.
Follow David Sabatini:
About Broad Institute, KSQ Therapeutics, Navitor Pharmaceuticals, Raze Therapeutics, The Howard Hughes Medical Institute: KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
Peter M. Hecht
Co-Founder & CEO of Cyclerion Therapeutics
Peter Hecht has served as Ironwood’s CEO and a director since co‐founding the company in 1998. He started Ironwood because he was attracted to “the idea of working with a team of people who challenge, inspire and humble me,” and building an enduring organization dedicated to creating important medicines. Under his leadership, Ironwood has grown from nine Ph.D. scientists to a fully‐integrated research, development and commercial organization. Prior to founding Ironwood, Peter was a research fellow at Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology (MIT). He earned his Ph.D. in molecular biology from the University of California at Berkeley as well as a B.S. in mathematics and an M.S. in biology from Stanford University.
Follow Peter M. Hecht:
About Cyclerion Therapeutics: Cyclerion Therapeutics is a clinical-stage biopharmaceutical company.
James P. Allison
Founder of Jounce Therapeutics
James Allison is a co-founder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of T-cell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the T-cell antigen receptor protein. His research led to the clinical development of ipilimumab (Yervoy™), which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program at the Memorial Sloan-Kettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial Sloan-Kettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as president of the American Association of Immunologists. He has received numerous awards, including the Centeon Award for Innovative Breakthroughs in Immunology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the AAI-Dana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. Dr. Allison recently received an AACR/SU2C/CRI cancer immunotherapy dream team grant, for which he will serve as the Dream Team leader. Dr. Allison received his B.S. in microbiology and his Ph.D. in biological sciences from the University of Texas.
Follow James P. Allison:
About Jounce Therapeutics, Memorial Sloan – Kettering Cancer Center, Neon Therapeutics: Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Richie Bavasso
Founder and CEO of nQ Medical
Mr. Bavasso is one of the early pioneers of use of digital media, devices and the web as tools to support pharmaceutical sales and marketing strategies and tactics. Since 1999, he has worked with top 25 Pharma clients globally to introduce the Closed Loop Marketing (CLM) function. He has set procedure and precedent in the areas of sales force effectiveness, business-rule driven content management, multichannel marketing, and mobile technology. A frequent speaker at industry conferences and events, Mr. Bavasso serves as an advocate for the industry in promoting digital conversation as integral to the various enterprise functions within pharma and the medical community. Prior to his seven years as co-founder and President of Exploria SPS, Mr. Bavasso served for sixteen years as CEO of Pharmedica Holdings, LLC, and President of its INFLUENT Division, at the time one of the largest medical education companies in the world. He built Pharmedica holdings from its start as a meetings planning company in 1992, doubling its revenues each year until its sale in 2001. This growth included an ACCME accredited entity (Center for Medical Education, LLC), a digital content division (Influent, LLC), and a call center (ContextMedicus, LLC). He opened offices in California, Connecticut, Illinois, and North Carolina. After his three-year earn out, Bavasso partnered to co-found Exploria SPS, LLC, as the mobile devices division of Exploria, Inc. Within three years, Exploria SPS became the market leader for CLM with offices in Connecticut and France and currently licenses software in 33 countries and 18 languages. Mr. Bavasso’s introduction of CLM and subsequent influence over the growth and expansion of CLM globally led to his recognition in 2007, by PharmaVoice magazine as one of the top 100 most influential people in pharma. Foreseeing the trends in Pharma that have impacted its selling model and the changing influence dynamic of payors on prescribing, Mr. Bavasso incubated a new and disruptive concept meant to serve as the transaction-fed, new marketplace for healthcare. This led to the incorporation of RIMEDIO, Inc. in October 2012 intent on reshaping the dynamic of how healthcare interacts and transacts to achieve mutual stakeholder objectives. RIMEDIO leverages the power of social utilities with eCommerce, content management and communications tools to consummate transactions between healthcare stakeholders. He is currently co-founder and CEO of nQ Medical, Inc., a machine learning computational biomarker company leveraging keyboard data to manage neuromotor diseases. Everyone has a unique typing signature. Research has revealed that the way we interact with computers and mobile devices can reveal with startling accuracy the presence of certain neuro-motor diseases. This Massachusetts Institute of Technology discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms. Mr. Bavasso is also a licensed hospital administrator having served from 1981 to 1992 leading two health care systems in New England. A graduate of Pepperdine University, Malibu, CA, with a Bachelor of Science degree in business administration, he received his MBA in health care management and finance from Bryant University, Smithfield, RI.
Follow Richie Bavasso:
About nQ Medical: nQ Medical is a neurotechnology company allowing Data Defined Disease Management via digital biomarkers using AI.
Shuhao Wen
Co-Founder of XtalPi
Shuhao Wen is a Co-Founder at XtalPi.
Follow Shuhao Wen:
About XtalPi: XtalPi is a biotech firm that uses artificial intelligence and computing to accelerate the development of new pharmaceutical drugs.
Alexander Klibanov
Co-Founder of Pulmatrix
Alexander Klibanov is the Novartis Professor of Chemistry and Bioengineering at the Massachusetts Institute of Technology. Alexander’s research interests include enzyme chemistry and biotechnology, protein drug delivery and formulation, stability and stabilization of pharmaceutical proteins and biochemistry in extreme environments. Alexander is a Member of the National Academy of Science and is known for greatly advancing the field of non-aqueous enzymology, the development methods for allowing enzymes to function in media such as organic solvents, rather than water. Alexander has authored over 270 scientific papers and has 16 issued U.S. patents. Alexander has given over 350 invited presentations and is a member of eight journal editorial boards. Alexander has received numerous prestigious professional awards including the Leo Friend Award, the Ipatieff Prize, the Marvin J. Johnson Award and the Arthur C. Cope Scholar Award, all from the American Chemical Society, as well as the International Enzyme Engineering Award. Dr. Klibanov is a member of both the U.S. National Academy of Sciences and the National Academy of Engineering. In addition, Alexander has started several biotechnology companies and has been a Member of the Scientific Advisory Board at BIND Therapeutics and SiO2 Medical Products.
Follow Alexander Klibanov:
About Arsia Therapeutics, Massachusetts Institute of Technology, Pulmatrix: Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.
David R. Elmaleh
Scientific Founder, CEO and Chairman of AZTherapies
David R. Elmaleh is the founder of [Mersana Therapeutics](https://www.crunchbase.com/organization/mersana-therapeutics#/entity). Previously, he served as the chairman and president of AZTherapies. Elmaleh obtained a bachelor’s degree in chemistry and physics, and master’s degree and PhD in organic chemistry from Hebrew University.
Follow David R. Elmaleh:
About AZTherapies, Mersana Therapeutics: AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Nick Plugis
Co-Founder & Chief Innovation Officer of Cellarity
Nicholas joined Flagship Pioneering as an associate after completing the VentureLabs Fellows Program. At Flagship, Nicholas conducts explorations to discover unexplored biological mechanisms and new biotechnologies. As part of a venture team of entrepreneurial scientists, he develops the science, intellectual property and business strategy that form the foundation of breakthrough startups. Prior to joining Flagship Pioneering, Nicholas earned his Ph.D. in chemistry at Stanford University in the laboratory of Professor Chaitan Khosla, where he developed novel chemical tools and animal models to investigate the molecular mechanisms underlying celiac disease. During his graduate studies, Nicholas completed the Stanford Ignite Program at the Graduate School of Business; he and his team developed the commercialization strategy for a Stanford-based medical diagnostic startup. Nicholas also served as vice president of SCIMALS, a non-profit organization that provides scientific and market due diligence to early-stage life science investors and aspiring entrepreneurs. Nicholas received his B.A. in both chemistry and economics from Middlebury College, conducting research with Professor Jim Larrabee on the reaction mechanisms of metal-containing enzymes utilizing inorganic electron microscopy.
Follow Nick Plugis:
About Cellarity, Flagship Pioneering: Cellarity’s platform digitizes the molecular information in cells to elucidate how they behave in health and disease.
Glenn Larsen
Co-Founder, President & CEO of Aquinnah Pharmaceuticals
Glenn Larsen is a Co-Founder, President & Chief Executive Officer at Aquinnah Pharmaceuticals since 2014. Aquinnah is a pharmaceutical company focused on the development of new therapies for ALS and neurodegenerative diseases. Glenn brings significant experience from his tenure in the discovery, development and commercialization of pharmaceutical, biotech and regenerative medicines, including raising approximately $65 million in private venture funding. Glenn has been closely involved with the commercial registration of five biologics and led teams that advanced over 15 new biologic and small molecule chemical entities to clinical development. Previously, Glenn was the Vice President of Musculoskeletal Sciences at Wyeth (Pfizer); directing R&D in the fields of arthritis, pain, inflammation and tissue regeneration, including responsibility for the global development and commercial efforts of Enbrel, an anti-TNF therapeutic. Glenn also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration programs. Glenn currently serves on the Board of Directors of Aquinnah Pharmaceuticals, Anika Therapeutics, 180 Therapeutics and previously Hydra Biosciences; and has held prior senior executive leadership roles at Hydra Biosciences and SpringLeaf Therapeutics. Glenn received his Ph.D. in Biochemistry from Stony Brook University and is a PMD Graduate of Harvard Business School.
Follow Glenn Larsen:
About Aquinnah Pharmaceuticals: Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
Danny Reinberg
Founder of Constellation Pharmaceuticals
Professor of Biochemistry, New York University School of Medicine Howard Hughes Medical Institute Investigator
Follow Danny Reinberg:
About Constellation Pharmaceuticals, Fulcrum Therapeutics: Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.
Yang Shi
Founder of Constellation Pharmaceuticals
Professor of Cell Biology, HMS and Merton Bernfield Professor of Neonatology at Children’s Hospital
Follow Yang Shi:
About Constellation Pharmaceuticals: Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.
Shravane Balabasqer
Founder | CEO of Carbon Analytics
Follow Shravane Balabasqer:
About Carbon Analytics: A granular asset focused carbon intelligence & offsetting platform for active industrial decarbonisation across the value chain.
Simon Read
Founder and CEO of Curie Therapeutics
Simon Read is the Founder and CEO Curie Therapeutics.
Follow Simon Read:
About Curie Therapeutics: Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Florian Ruker
Co-Founder of F-star Therapeutics
Florian Rüker received his doctorate from the University of Natural Resources and Life Sciences, Vienna, Austria, where he is leading a research group working in the field of protein structural biology, engineering and expression, with a focus on antibodies and serum albumin. For several years, he has also been active as a project leader for New Century Pharmaceuticals Inc. (Huntsville, AL). At present, he is Professor at the Department of Biotechnology at BOKU and a Co-leader of the Christian Doppler Laboratory for Antibody Engineering. He is Co-founder of F-star and inventor of F-star’s core antibody engineering technology.
Follow Florian Ruker:
About F-star Therapeutics, University of Natural Resources and Life Sciences: F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Nawaz Khan
Research Director, Co-Founder of Discuva
Nawaz Khan is the VP Anti-infectives Research at Summit Therapeutics.
Follow Nawaz Khan:
About Discuva, Summit Therapeutics: Antibacterial discovery research has been driven, medically, commercially
Jane Osbourn
Co-Founder, Chief Scientific Officer & Chief Technology Officer of Alchemab Therapeutics
Jane Osbourn is the chairman at Mogrify.
Follow Jane Osbourn:
About Alchemab Therapeutics: Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Dave Peck
Co Founder & Consultant of Genometry
Follow Dave Peck:
About Broad Institute, Genometry: Genometry commercializes a genome-wide, high-throughput, gene-expression profiling method for pharmaceutical discovery applications.
Paul-Peter Tak
Founder of Sitryx Therapeutics
Follow Paul-Peter Tak:
About Candel Therapeutics, Sitryx Therapeutics: Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Gordon McInroy
Founder and CTO of Nuclera
Follow Gordon McInroy:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Salvatore Mascia
Founder & President of CONTINUUS Pharmaceuticals
Salvatore Mascia is the Founder & CEO of CONTINUUS Pharmaceuticals. He was the former Strategic Project Manager at the Novartis-MIT Center for Continuous Manufacturing, where he led the integration of the first end-to-end continuous manufacturing process for pharmaceuticals. At the end of the project, he was presented with the “Leadership Award” that recognized his leadership role at the Center. Salvatore has gained experience in strategic management and fund raising in addition to leadership skills via various roles of responsibility within the entrepreneurial ecosystem. Among those, he co-founded “Professionisti Italiani a Boston” in 2009, and served as President of the “Cambridge University Technology and Enterprise Club” in 2006/07. He also ran a pharmacy business for 2 years. Salvatore completed a post-doc at MIT in Chemical Engineering and holds a PhD in Chemical Engineering from the University of Cambridge, UK and a BS and MS in Pharmacy (summa cum laude) from University of Perugia, Italy.
Follow Salvatore Mascia:
About CONTINUUS Pharmaceuticals: Continuus Pharmaceuticals designs, builds, and runs manufacturing processes for pharmaceutical and generic clients.
Gleb Kuznetsov
Co-Founder and CEO of Manifold Bio
Gleb Kuznetsov is the Co-Founder and CEO at Manifold Bio.
Follow Gleb Kuznetsov:
About Manifold Bio: Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement.
Pierce Ogden
Co-Founder and CSO of Manifold Bio
Pierce Ogden is the Co-Founder and CSO at Manifold Bio.
Follow Pierce Ogden:
About Manifold Bio: Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement.
Scott Martin
Co-Founder, Vice-Chairman, and Executive Vice President of Inspiration Biopharmaceuticals
Follow Scott Martin:
About Inspiration Biopharmaceuticals: Inspiration Biopharmaceuticals develops recombinant blood coagulation factor products for the treatment of hemophilia.
James Bradner
Founder of Tensha Therapeutics
Dr. Bradner is a chemical biologist and hematologist at the Dana-Farber Cancer Institute and Harvard Medical School. He is a graduate of Harvard College, the University of Chicago-Pritzker School of Medicine and Harvard Medical School-Health Sciences and Technology. He completed internship and residency in Internal Medicine at the Brigham & Women’s Hospital, followed by Hematology and Medical Oncology training in the combined Dana-Farber/Partners Cancer Care Fellowship Program. He completed post-doctoral research training under the mentorship of Professor Stuart Schreiber, PhD in the Department of Chemistry & Chemical Biology at Harvard University and the Broad Institute of Harvard and MIT. In 2009, he joined the research faculty of the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Bradner is an Associate Member of the Broad Institute and affiliated faculty in the Chemical Biology Program of Harvard Medical School. He has published in many prestigious journals and is a member of the American Society of Hematology and the American Chemical Society. He is board-certified in Hematology, Oncology and Internal Medicine. Dr. Bradner’s specific interests include the development of direct-acting inhibitors of transcriptional complexes and isoform-selective inhibitors of chromatin-modifying enzymes.
Follow James Bradner:
About Tensha Therapeutics: Tensha Therapeutics develops small molecule bromodomain inhibitors to treat cancer and other serious disorders.
Xiaofei Gao
Chairman & Founder of Westlake Therapeutics
Xiaofei Gao is the Founder of Westlake Therapeutics.
Follow Xiaofei Gao:
About Westlake Therapeutics: The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
